FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156492908> ?p ?o ?g. }

• W2156492908 endingPage "36" @default.
• W2156492908 startingPage "27" @default.
• W2156492908 abstract "The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R) and without (MPR) lenalidomide maintenance. The efficacy, safety, and cost-effectiveness of these regimens have not yet been compared; therefore, we conducted a pharmacoeconomic analysis using data from randomized controlled trials versus MP. Using a Markov model developed from a U.S. payer's perspective, we compared VMP with MPT and MPR-R over a lifetime horizon. MPT and MPR-R were chosen because, like VMP, they are superior to MP in response and outcomes. Data from the Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA; VMP), Intergroupe Francophone du Myelome (IFM) 99-06 (MPT), and MM-015 (MPR-R) trials were used. The IFM 99-06 study was selected because of the superior activity in this study compared with other MPT studies. Using patient-level (VMP) and published (MPT, MPR-R) data, we estimated the health-state transition and adverse event probabilities for each regimen, related costs, and state-specific utility estimates. Costs (in 2010 U.S. dollars) and health outcomes were discounted at 3%. Discounted lifetime direct medical costs were lowest with VMP at $119,102. MPT cost $142,452 whereas MPR-R cost $248,358. Incremental cost-effectiveness ratio calculations projected that VMP would confer cost savings and better health outcomes relative to MPT and MPR-R. We conclude that VMP is highly likely to be cost-effective compared with MP, MPT, and MPR-R." @default.
• W2156492908 created "2016-06-24" @default.
• W2156492908 creator A5017279132 @default.
• W2156492908 creator A5019718106 @default.
• W2156492908 creator A5034389447 @default.
• W2156492908 creator A5039244845 @default.
• W2156492908 creator A5049970120 @default.
• W2156492908 creator A5060404340 @default.
• W2156492908 creator A5060938706 @default.
• W2156492908 creator A5063896009 @default.
• W2156492908 creator A5065718444 @default.
• W2156492908 creator A5066594351 @default.
• W2156492908 creator A5078545131 @default.
• W2156492908 creator A5079485616 @default.
• W2156492908 date "2013-01-01" @default.
• W2156492908 modified "2023-10-05" @default.
• W2156492908 title "The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment" @default.
• W2156492908 cites W1536921365 @default.
• W2156492908 cites W1556628912 @default.
• W2156492908 cites W1841854979 @default.
• W2156492908 cites W1965249739 @default.
• W2156492908 cites W1973912471 @default.
• W2156492908 cites W1990152834 @default.
• W2156492908 cites W2028399237 @default.
• W2156492908 cites W2066800926 @default.
• W2156492908 cites W2082741854 @default.
• W2156492908 cites W2085092835 @default.
• W2156492908 cites W2095950656 @default.
• W2156492908 cites W2096207943 @default.
• W2156492908 cites W2101576302 @default.
• W2156492908 cites W2103289287 @default.
• W2156492908 cites W2110466835 @default.
• W2156492908 cites W2115181643 @default.
• W2156492908 cites W2117172636 @default.
• W2156492908 cites W2142704172 @default.
• W2156492908 cites W2143860449 @default.
• W2156492908 cites W2341609337 @default.
• W2156492908 cites W2474872853 @default.
• W2156492908 cites W2520815307 @default.
• W2156492908 cites W2552386890 @default.
• W2156492908 cites W2554414226 @default.
• W2156492908 cites W2993095404 @default.
• W2156492908 cites W3004313685 @default.
• W2156492908 doi "https://doi.org/10.1634/theoncologist.2011-0380" @default.
• W2156492908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3556252" @default.
• W2156492908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23299777" @default.
• W2156492908 hasPublicationYear "2013" @default.
• W2156492908 type Work @default.
• W2156492908 sameAs 2156492908 @default.
• W2156492908 citedByCount "50" @default.
• W2156492908 countsByYear W21564929082013 @default.
• W2156492908 countsByYear W21564929082014 @default.
• W2156492908 countsByYear W21564929082015 @default.
• W2156492908 countsByYear W21564929082016 @default.
• W2156492908 countsByYear W21564929082018 @default.
• W2156492908 countsByYear W21564929082019 @default.
• W2156492908 countsByYear W21564929082020 @default.
• W2156492908 countsByYear W21564929082021 @default.
• W2156492908 countsByYear W21564929082022 @default.
• W2156492908 countsByYear W21564929082023 @default.
• W2156492908 crossrefType "journal-article" @default.
• W2156492908 hasAuthorship W2156492908A5017279132 @default.
• W2156492908 hasAuthorship W2156492908A5019718106 @default.
• W2156492908 hasAuthorship W2156492908A5034389447 @default.
• W2156492908 hasAuthorship W2156492908A5039244845 @default.
• W2156492908 hasAuthorship W2156492908A5049970120 @default.
• W2156492908 hasAuthorship W2156492908A5060404340 @default.
• W2156492908 hasAuthorship W2156492908A5060938706 @default.
• W2156492908 hasAuthorship W2156492908A5063896009 @default.
• W2156492908 hasAuthorship W2156492908A5065718444 @default.
• W2156492908 hasAuthorship W2156492908A5066594351 @default.
• W2156492908 hasAuthorship W2156492908A5078545131 @default.
• W2156492908 hasAuthorship W2156492908A5079485616 @default.
• W2156492908 hasBestOaLocation W21564929081 @default.
• W2156492908 hasConcept C112930515 @default.
• W2156492908 hasConcept C126322002 @default.
• W2156492908 hasConcept C143998085 @default.
• W2156492908 hasConcept C2776063141 @default.
• W2156492908 hasConcept C2776364478 @default.
• W2156492908 hasConcept C2777478702 @default.
• W2156492908 hasConcept C2778684742 @default.
• W2156492908 hasConcept C2778720950 @default.
• W2156492908 hasConcept C2779609412 @default.
• W2156492908 hasConcept C2781413609 @default.
• W2156492908 hasConcept C3019080777 @default.
• W2156492908 hasConcept C71924100 @default.
• W2156492908 hasConceptScore W2156492908C112930515 @default.
• W2156492908 hasConceptScore W2156492908C126322002 @default.
• W2156492908 hasConceptScore W2156492908C143998085 @default.
• W2156492908 hasConceptScore W2156492908C2776063141 @default.
• W2156492908 hasConceptScore W2156492908C2776364478 @default.
• W2156492908 hasConceptScore W2156492908C2777478702 @default.
• W2156492908 hasConceptScore W2156492908C2778684742 @default.
• W2156492908 hasConceptScore W2156492908C2778720950 @default.
• W2156492908 hasConceptScore W2156492908C2779609412 @default.
• W2156492908 hasConceptScore W2156492908C2781413609 @default.
• W2156492908 hasConceptScore W2156492908C3019080777 @default.
• W2156492908 hasConceptScore W2156492908C71924100 @default.

• next